… results from this open-label, phase-IV, follow-up study of efficacy, safety and tolerability of
gefitinib in Caucasian patients with EGFR mutation-positive NSCLC. Exploratory biomarker …

Background We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of PD-…

Introduction The FIR phase II study (NCT01846416 ) evaluated the efficacy and safety of anti–programmed
death-ligand 1 (PD-L1) atezolizumab in advanced NSCLC selected by tumor …

… Furthermore, patients treated with nivolumab plus … treatment for adult patients with metastatic
NSCLC expressing PD-… option for eligible patients with metastatic NSCLC with either tumor …

… Moreover, for patients with nonsquamous NSCLC, the addition of first-line bevacizumab to
… Therefore, we believe that there is still a substantial proportion of patients with NSCLC who …

… This open-label, phase 1b study enrolled patients with advanced EGFR-mutated NSCLC. In
… and was found to have efficacy in patients with NSCLC central nervous system metastases. …

… paclitaxel dosing in patients with advanced non-small-cell lung cancer (NSCLC) to avoid …
Patients and methods Patients with newly diagnosed, advanced NSCLC were randomly …

… In this multicentre, international, randomised, open-label, phase 3 trial, we recruited patients
with treatment-naive, stage IV NSCLC in 102 sites in 16 countries. Eligible patients had …

… We report safety and clinical activity in patients (pts) with advanced NSCLC progressing …
Conclusions: In pts with previously treated NSCLC, avelumab was administered safely with a …

… advanced NSCLC in over 90 countries. In 2016, crizotinib was also approved in the United
States and European Union for the treatment of patients with advanced NSCLC whose …